SV

Street Verdict

Analyst Scorecard

A record of what Rajiv Batra said publicly, with the source. Not advice.

Pending — not yet graded
“Recommends profit-taking in the pharma sector due to concerns over US generics, including potential Section 232 investigations, and underwhelming earnings in the recently concluded quarter. The sector has seen a 40% outperformance over the last three years, making it prudent to reduce exposure given the overhanging risks and high 26x PE valuations.”
Nifty PharmaBearishCalled 22 Aug 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Rajiv Batra’s full track record